Skip to main content
  • Contact Us
  • Bayer AG
Go to Patient Area

To visit the Global Nebido® website, please choose from the options below:

  • I am an HCP
  • I am a patient

To visit the Global Nebido® website, please choose from the options below:

  • I am an HCP
  • I am a patient
Alt
Go to Patient Area
  • Home
  • Hypogonadism
    • Overview
    • About hypogonadism
    • Classification of hypogonadism
    • Risk factors for hypogonadism
    • What are symptoms of hypogonadism?
    • How to diagnose hypogonadism?
    • Practical advice for diagnosing hypogonadism
    • Diagnosis and treatment algorithm
    • Myths and facts about hypogonadism
  • Testosterone therapy
    • Overview
    • Treatment guidelines
    • Treatment options
    • Benefits of testosterone therapy
    • Safety of testosterone therapy
    • Testosterone therapy practical advice
    • Nebido® treatment tracker
    • Anabolic abuse
  • Product information
    • Overview
    • Nebido®
    • Nebido® monograph
    • Nebido® prescribing information
    • Select your country
    • IM injection
  • Tools
    • Overview
    • AMS questionnaire
    • ADAM questionnaire
    • Testosterone conversion
    • Free testosterone calculator
    • Testosterone management tool
    • Testosterone effects tool
    • HOMA-IR tool
    • Waist-to-height ratio calculator
  • T4DM study
  • FAQs
    • Overview
    • FAQs Nebido®
    • FAQs hypogonadism
  • Research news
  • Resources
    • Overview
    • Information resources
    • Events
    • Conferences
    • Educational links
    • Download center
    • Podcasts
  • Country select
    • Country 1
    • Country 2
  • Contact Us
  • Bayer AG
Alt tag

Educational links

Access educational modules on hypogonadism and related conditions

Bayer logo Bayer logo Bayer logo Bayer logo

Breadcrumb

  1. Home
  2. Resources
  3. Educational links
medscape eau

To view the CME, MedScape requires visitors to create a free account.

 

    A patient with diabetes, obesity, and lower urinary tract symptoms (LUTS)

    1. A patient with diabetes, obesity, and lower urinary tract symptoms (LUTS)

    medsims

    Patient simulation cases

    The goal of this activity is to provide guidance to clinicians who treat male patients with LUTS symptoms and comorbidities regarding appropriate clinical workup, diagnosis, and treatment options, based on clinical data and guidelines, expert opinion, and patient preference to optimize individualized patient care.

    Further Information
    Read more

    Experts

    Alex W
    Alex W. Pastuszak, MD, PhD
    Assistant Professor, Division of Urology
    Department of Urology,
    Department of Surgery,
    University of Utah,
    Salt Lake City, Utah, United States
    Hugh Jones
    Hugh Jones, BSc, MD, FRCP
    Professor, Barnsley Hospital NHS Foundation Trust,
    University of Sheffield, Barnsley, South Yorkshire, United Kingdom

    Learning objectives

    Upon completion of this activity, participants will:

    • Have greater competence related to
      • Diagnosing a patient with comorbid medical disorders, who also has lower urinary tract symptoms (LUTS)
      • The development of individualized treatment plans based on guidelines, expert guidance, and patient preference

    Target audience

    This educational activity is intended for an international audience of urologists, primary care physicians, diabetologists and endocrinologists who practice outside of the US.

    Dot Dot Dot
    Next
    Hypogonadism and cardiovascular and metabolic health: should we consider testosterone replacement?

    2. Hypogonadism and cardiovascular and metabolic health: should we consider testosterone replacement?

    Test-and-teach

    This activity is intended to improve physicians’ knowledge regarding the recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions, best practice for the accurate detection and diagnosis of male hypogonadism, and optimal treatment strategies for men with hypogonadism.

    Further Information
    Read more

    Experts

    Geoffrey Hackett
    Geoffrey Hackett, MD, FRCPI, MRCGP
    Professor of Sexual Medicine, Aston University Birmingham;
    Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
    Birmingham, United Kingdom

    Learning objectives

    Upon completion of this activity, participants will be able to:

    • Have increased knowledge of:
      • Hypogonadism in men and its impact on overall health and wellbeing.
      • Recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions.
    • Demonstrate greater competence in their ability to:
      • Accurately detect and diagnose male hypogonadism.
      • Employ best practice in the safe and effective treatment of men with hypogonadism.

    Target audience

    This educational activity is intended for an international audience of non-US healthcare professionals, specifically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

    Previous
    Dot Dot Dot
    Next
    New perspectives on hypogonadism and testosterone replacement in clinical practice

    3. New perspectives on hypogonadism and testosterone replacement in clinical practice

    Expert column

    The goals of this activity are to help participants identify patients with hypogonadism; provide an overview of the impact of the condition on quality of life and mortality; and review the role of testosterone therapy in prostate, metabolic, and cardiovascular health.

    Further Information
    Read more

    Experts

    Alvaro Morales
    Alvaro Morales, MD, FRCSC, FACS
    Professor Emeritus,
    Department of Urology,
    School of Medicine, Queen's University,
    Kingston, Ontario, Canada
    Abraham Morgentaler
    Abraham Morgentaler, MD, FACS
    Founder and Director, Men's Health Boston;
    Associate Clinical Professor of Surgery (Urology), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States
    Geoffrey Hackett
    Geoffrey Hackett, MD, FRCPI, MRCGP
    Professor of Sexual Medicine, Aston University Birmingham;
    Consultant in Urology and Sexual Medicine, University Hospitals Birmingham, United Kingdom
    Michael Zitzmann
    Michael Zitzmann, MD, PhD
    Professor of Medicine, Endocrinologist, Andrologist, Diabetologist; Sexual Medicine (FECSM); Clinical Andrology Centre for Reproductive Medicine and Andrology, Münster, Germany

    Learning objectives

    Upon completion of this activity, participants will be able to:

    • Identify the clinical impact of testosterone deficiency on men’s health, quality of life, and mortality
    • Examine the latest clinical data on the interrelationships between hypogonadism and metabolic and cardiovascular risk factors, and between hypogonadism and prostate health
    • Explain how to identify men at risk, diagnose hypogonadism, and how to treat and monitor patients, taking into account the latest clinical data and guidelines

    Target audience

    This educational activity is intended for an international audience of non-US healthcare professionals, specifically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

    Previous
    Dot Dot Dot

    Recommendations

    Long term therapy with Nebido<sup>&reg;</sup>

    Long term therapy with Nebido®

    Download center

    Download center

    Related topics

    Hypogonadism Therapy Product information
    • General conditions of use
    • Imprint
    • Privacy statement
    • Prescribing information
    • Sitemap

    Copyright © 2021, Bayer AG

    This website contains information on Nebido® (testosterone undecanoate) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission.

     

    This website is intended to provide information to an international audience outside Austria, France, Germany, Hungary, Ireland, the Middle East, the Philippines, Thailand, the UK, and the USA.

    Page last modified 01/04/2021

    PP-NEB-ALL-0222-1 April 2021

    • PP-NEB-ALL-0222-1 April 2021

    BayerBayer

    hidden link for autofocus
    Cookie consent image